Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover ...

The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Medicare coverage of weight loss drugs, if authorized, is seen increasing federal spending by about $35B from 2026 to 2034.

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...

Covering weight-loss drugs for elderly Americans on the state-backed Medicare health insurance programme would cost the US government $35bn over the next nine years, a congressional analysis has found ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...